Arimoclomol

Arimoclomol
Clinical data
Trade namesMiplyffa
AHFS/Drugs.comMonograph
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
  • N-[(2R,Z)-2-hydroxy-3-(1-piperidyl)propoxy]pyridine-3-carboximidoyl chloride 1-oxide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H20ClN3O3
Molar mass313.78 g·mol−1
3D model (JSmol)
  • O[C@H](CN1CCCCC1)CO\N=C(\Cl)c2ccc[n+]([O-])c2
  • InChI=1S/C14H20ClN3O3/c15-14(12-5-4-8-18(20)9-12)16-21-11-13(19)10-17-6-2-1-3-7-17/h4-5,8-9,13,19H,1-3,6-7,10-11H2/b16-14+/t13-/m1/s1 checkY
  • Key:SGEIEGAXKLMUIZ-ZPTIMJQQSA-N checkY
 X markNcheckY (what is this?)  (verify)

Arimoclomol, sold under the brand name Miplyffa, is a medication used for the treatment of Niemann–Pick disease type C. It is taken by mouth.

The most common side effects include upper respiratory tract infection, diarrhea, and decreased weight.

Arimoclomol was approved for medical use in the United States in September 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.